ATNM

Actinium is a clinical-stage company with, by its own admission, "no revenue from commercial sales to date" — the $90K booked in FY2025 is an NIH grant reimbursement, not product sales, which makes the headline P/S of 342 economically meaningless. The whole business is a bet on unapproved pipeline candidates (ATNM-400, Actimab-A, Iomab-ACT). The MD&A and Risk Factors are explicit that the company "has incurred net losses every year since inception" and expects to keep doing so, and that without additional financing it "will be unable to continue or complete" development. A -$410M accumulated deficit against $7.83M of book equity is the eleven-year scorecard.

The balance sheet is the crux. Cash fell 34% to $48.0M while operating cash burn ran -$24.6M — roughly two years of runway before another raise, and the second-quarter 2025 14% workforce cut plus a 30% drop in R&D signal a company conserving cash, not accelerating. Stockholders' equity cratered 76% to $7.83M, and the 5.61x liabilities/equity ratio is dominated by the $35.0M Immedica deferred license liability that only converts to income if the EU approves Iomab-B — or is written off if it's rejected. That single regulatory event is a genuine binary. Revenue history is not a growth story but noise around zero: $1.14M (2021) → $81K (2023) → $90K (2025).